- Home
- REFI vs STRO Comparison
REFI vs STRO Comparison
Compare REFI & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | STRO |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 85.0M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | REFI | STRO |
|---|---|---|
| Price | $12.82 | $11.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 8 |
| Target Price | ★ $20.00 | $18.29 |
| AVG Volume (30 Days) | ★ 149.6K | 129.5K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 16.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | $54,287,847.00 | ★ $105,646,000.00 |
| Revenue This Year | $13.78 | $63.08 |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | $7.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.85 | $5.23 |
| 52 Week High | $16.27 | $21.50 |
Technical Indicators
Market Signals| Indicator | REFI | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 48.12 | 78.83 |
| Support Level | $12.72 | $8.49 |
| Resistance Level | $13.20 | $12.00 |
| Average True Range (ATR) | 0.28 | 0.83 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 16.87 | 79.85 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.